$2.11+0.01 (+0.48%)
Autonomix Medical Inc. (AMIX) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 3 wire items for AMIX, including 2 press releases and news items and 1 insider trade. The most recent was published Oct 13, 2026.
Price$2.11-0.57 (-21.27%)
2026-07-282026-10-28
News · 26 weeks45-93%
2026-05-032026-10-25
Mix2790d
- SEC Filings12(44%)
- Other9(33%)
- Insider5(19%)
- Leadership1(4%)
Latest news
25 items- INSIDERSEC Form 3 filed by Autonomix Medical Inc.3 - Autonomix Medical, Inc. (0001617867) (Issuer)
- PRAutonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural ValidationPatent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies THE WOODLANDS, TX, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 3,183,802, titled, "Systems, Methods, and Devices for Monitoring and Treatment of Tissues
- PRAutonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. ClearanceFDA pre-submission feedback supports a Class II strategy, leveraging substantial equivalence to a previously cleared device, positioning the Company for potential initial U.S. clearance of its standalone sensing platform in approximately 15 months THE WOODLANDS, TX, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of a pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the Company’s recently announced standalone transvascular sensing platform, which is designed to detect and dif
- PRAutonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation PlatformEuropean patent strengthens protection for proprietary autonomic nervous system assessment technologies, further expanding Company's international patent portfolio THE WOODLANDS, TX, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the grant of European Patent No. EP 4 233 700 B1, titled "Systems for Assessing Neural Activity in an Eye." The newly issued patent further expands the Company's international intellectual property portfolio and strengthens protection for technologies supporting autonomic nervous system assessment and preci
- INSIDERCFO Smith Trent N. was granted 15,000 shares, increasing direct ownership by 12,605% to 15,119 units (SEC Form 4)4 - Autonomix Medical, Inc. (0001617867) (Issuer)
- SECSEC Form 424B3 filed by Autonomix Medical Inc.424B3 - Autonomix Medical, Inc. (0001617867) (Filer)
- SECAutonomix Medical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Autonomix Medical, Inc. (0001617867) (Filer)
- PRAutonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of DirectorsAppointment adds more than four decades of MedTech leadership, FDA regulatory and strategic transaction experience, including work supporting renal denervation and other category-defining technologies THE WOODLANDS, TX, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the appointment of Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel of Medtronic plc (Medtronic) as a Board Member for Autonomix. Ms. Kalter brings more than four decades of experience across the medical device and healthcare industries, includi
- SECSEC Form EFFECT filed by Autonomix Medical Inc.EFFECT - Autonomix Medical, Inc. (0001617867) (Filer)
- SECSEC Form DEFA14A filed by Autonomix Medical Inc.DEFA14A - Autonomix Medical, Inc. (0001617867) (Filer)
- SECSEC Form DEF 14A filed by Autonomix Medical Inc.DEF 14A - Autonomix Medical, Inc. (0001617867) (Filer)
- SECSEC Form 424B5 filed by Autonomix Medical Inc.424B5 - Autonomix Medical, Inc. (0001617867) (Filer)
- INSIDERDirector Klemp Walter V was granted 13,000 shares, increasing direct ownership by 183% to 20,118 units (SEC Form 4)4 - Autonomix Medical, Inc. (0001617867) (Issuer)
- INSIDERDirector Bisson Lori was granted 13,000 shares, increasing direct ownership by 10,924% to 13,119 units (SEC Form 4)4 - Autonomix Medical, Inc. (0001617867) (Issuer)
- INSIDERCEO and President Hauser Bradley was granted 27,000 shares (SEC Form 4)4 - Autonomix Medical, Inc. (0001617867) (Issuer)
- SECSEC Form PRE 14A filed by Autonomix Medical Inc.PRE 14A - Autonomix Medical, Inc. (0001617867) (Filer)
- SECSEC Form S-3 filed by Autonomix Medical Inc.S-3 - Autonomix Medical, Inc. (0001617867) (Filer)
- PRAutonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026Abstracts highlight potential of Autonomix’s transvascular technology across pain management and nervous system mapping THE WOODLANDS, TX, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that two scientific abstracts have been accepted for poster presentation at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2026 Annual Congress, taking place September 5-9, 2026, in Copenhagen, Denmark. The accepted abstracts, both presented by Dr. Robert Schwartz of Autonomix, highlight the potential of the Company’s t
- SECAutonomix Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits8-K - Autonomix Medical, Inc. (0001617867) (Filer)
- PRAutonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy DeliveryNew patent broadens protection around systems integrating real-time physiological feedback, sensing and imaging with controlled therapeutic delivery, including neural ablation approaches for cancer pain THE WOODLANDS, TX, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the issuance of U.S. Patent No. 12,714,780 by the United States Patent and Trademark Office (USPTO), titled "Systems and Methods for Regulating Organ and/or Tumor Growth Rates, Function, and/or Development" on August 25, 2026. The newly issued patent covers medical sys
- PRAutonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq RulesTHE WOODLANDS, TX, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor ("Investor") for the immediate exercise of certain outstanding warrants that the Company issued on July 15, 2026 (the "July 2026 Warrants"). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding July 2026 Warrants to purchase an aggregate of 857,462 shares of the Company’s common stock at the exercise price of $5.75. The resale of the shares of common stock issu
- SECSEC Form 10-Q filed by Autonomix Medical Inc.10-Q - Autonomix Medical, Inc. (0001617867) (Filer)
- PRAutonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA SubmissionFinal histology and laboratory analyses support the study’s safety and performance objectives THE WOODLANDS, TX, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the successful completion of its Good Laboratory Practice (GLP) pre-clinical study, a significant regulatory milestone supporting the Company's submission to the U.S. Food and Drug Administration (FDA). The study was conducted in accordance with FDA Good Laboratory Practice standards and evaluated the safety, functionality and performance of the Autonomix platform across mult
- PRAutonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement AwardRecognition honors one of the medical technology industry's most influential innovators, whose career has helped shape modern cardiovascular care THE WOODLANDS, TX, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today congratulated its Chief Medical Officer, Robert Schwartz, M.S., M.D., FACC, on being named the recipient of the 2026 Cardiovascular Tech Forum (CTF) Lifetime Achievement Award, recognizing his extraordinary career and lasting contributions to cardiovascular medicine, innovation and medical technology. Dr. Schwartz will be honored duri
- SECSEC Form EFFECT filed by Autonomix Medical Inc.EFFECT - Autonomix Medical, Inc. (0001617867) (Filer)
AMIX FAQ
6 questionsWhat is the latest news on AMIX?
In the last 30 days Quantisnow tracked 3 wire items for AMIX: 2 press releases and news items and 1 insider trade. The most recent was published on October 13, 2026.Where does AMIX stock trade?
Autonomix Medical Inc. (AMIX) is listed on NASDAQ.What sector and industry is AMIX in?
Autonomix Medical Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Autonomix Medical Inc. go public?
Autonomix Medical Inc. (AMIX) completed its IPO in 2024.What companies are similar to AMIX?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare AMIX side-by-side with any of them on Quantisnow.How can I track AMIX on Quantisnow?
Quantisnow aggregates Autonomix Medical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AMIX to receive live email and push alerts on every new disclosure.